LumaWave
Developing portable photoacoustic imaging for point-of-care diagnostics, initially focused on chronic-wound care.
Website: https://www.lumawaveimaging.com/
Cover Block
Open sources
| Field | Detail |
|---|---|
| Name | LumaWave |
| Tagline | Developing portable photoacoustic imaging for point-of-care diagnostics, initially focused on chronic-wound care. |
| Headquarters | New Orleans, United States [F6S] |
| Founded | 2025 [F6S] |
| Stage | Pre-Seed |
| Business model | Hardware + Software |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth profile | Venture Scale |
| Founding team | Academic Spinout |
| Funding label | Undisclosed |
Links
Open sources
- Website: https://www.lumawaveimaging.com/
- About: https://www.lumawaveimaging.com/about.html
- News: https://www.lumawaveimaging.com/news.html
- F6S: https://www.f6s.com/company/lumawave
What an Investor Needs First
PUBLIC LumaWave is a New Orleans medical-device startup developing portable photoacoustic imaging for point-of-care tissue oxygenation assessment, and it merits investor attention now because the company has moved from university spinout status into externally visible grant and competition activity, including a disclosed $1.5 million ARPA-H-linked award with Tulane in July 2026 [Tulane Research, July 2026] [Biz New Orleans, March 2026]. Founded in 2025, the company appears to have emerged from Tulane research, with its early narrative centered on translating photoacoustic imaging into bedside and clinic workflows rather than building a conventional imaging platform for hospital radiology departments [F6S] [Tulane Research, July 2026].
The current product thesis is straightforward: a handheld probe sends pulses of light into tissue and detects resulting ultrasound signals to identify low-oxygen areas in real time, with chronic-wound care as the initial commercial wedge and fetal monitoring as a visible adjacent program [Tulane Research, July 2026] [Biz New Orleans, November 2025]. The differentiation, as publicly described, rests on portability and lower-cost point-of-care deployment relative to existing tissue-oxygenation approaches, although most performance and cost claims remain company or university sourced rather than independently validated in clinical or commercial settings [news.tulane.edu] [LumaWave Inc.].
The founding team fits the academic-spinout pattern. CEO and co-founder Vinoin "Vin" Devpaul Vincely is described by Tulane and company materials as a recent Tulane PhD graduate who leads commercialization activity, while CTO and co-founder Carolyn L. Bayer is an associate professor of biomedical engineering at Tulane whose research background spans bioinstrumentation and optical imaging [Tulane Research, July 2026] [LumaWave Inc.]. That mix gives LumaWave technical credibility at inception, but the next proof point is execution outside the lab, particularly clinical adoption, regulatory path clarity, and evidence that the device can fit routine wound-care economics.
On capitalization, the public record supports non-dilutive and institutional backing more clearly than venture financing. No confirmed priced equity round or named investor appears in the available sources, while Tulane-related proof-of-concept support, a $15,000 Tulane Demo Day prize, and the ARPA-H-related award are visible indicators of early external validation; the stated model is hardware plus software, which implies a more capital-intensive commercialization path than software-only healthtech [Tulane Research, July 2026] [Biz New Orleans, March 2026] [LumaWave Inc.]. Over the next 12 to 18 months, the central watch items are whether LumaWave can convert grant momentum into named clinical partners, produce public validation data for chronic-wound or fetal applications, and define a financing strategy that matches the demands of a medical-device go-to-market [Biz New Orleans, November 2025] [Tulane Research, July 2026].
Claim stands unchecked -- This section relies materially on company and university sources, with limited independent corroboration from local business coverage.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Pre-Seed |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding | Undisclosed |
Inside the Company
PUBLIC
LumaWave presents as a very early Tulane spinout rather than a company with a long operating history. The public record indicates the company was founded in 2025, is based in New Orleans, and is building portable photoacoustic imaging for point-of-care diagnostics, with early emphasis on chronic-wound care [f6s.com, retrieved 2026] [lumawaveimaging.com, retrieved 2026]. The company website describes the platform as a point-of-care tissue vitality assessment product, and its team page identifies Vinoin "Vin" Devpaul Vincely as CEO and co-founder and Carolyn L. Bayer as CTO and co-founder [lumawaveimaging.com, retrieved 2026].
The visible milestones are academic and grant-linked, which is typical for a medical-device company still near formation. In November 2025, Biz New Orleans profiled LumaWave in coverage of Idea Village's Fall 2025 Pitch Night, describing a handheld tissue-oxygenation probe and a commercial focus on wound care [bizneworleans.com, November 2025]. By March 2026, the company had placed second at Tulane's $50K Demo Day, receiving a $15,000 award [bizneworleans.com, March 2026]. In July 2026, Tulane Research reported that Tulane researchers and LumaWave had received a $1.5 million ARPA-H award through the Making Obstetrics Care Smart program to advance fetal monitoring that directly measures fetal-tissue oxygen levels during pregnancy and labor [research.tulane.edu, July 2026].
Partially corroborated -- Confirmed primarily by the company website, with milestone corroboration from Biz New Orleans and Tulane Research.
Under the Hood
MIXED LumaWave is building a handheld photoacoustic imaging probe for point-of-care diagnostics, with the public record consistently centering on tissue oxygenation rather than a broad imaging platform [Tulane Research, July 2026] [Biz New Orleans, November 2025]. The core mechanism is straightforward in principle: the system sends pulses of light into tissue and detects the resulting ultrasound signals, producing a view into low-oxygen regions that conventional ultrasound does not directly measure [Tulane Research, July 2026]. The company and Tulane both frame the initial clinical wedge around chronic-wound care, where portable assessment of hypoxia could matter if the device performs as described in real workflows [Biz New Orleans, November 2025] [LumaWave Inc.].
The technical claim set is still early, and most of the stronger commercial language comes from company materials rather than independent validation. LumaWave says the probe enables real-time tissue vitality assessment and can be used in point-of-care or remote settings at lower cost than incumbent approaches, while Tulane's July 2026 write-up similarly describes a portable format intended to expand access to advanced imaging [LumaWave Inc.] [Tulane Research, July 2026]. More generally, the underlying modality is credible at the category level: photoacoustic imaging combines optical absorption with acoustic detection, a hybrid approach that has been studied across preclinical and clinical applications [Frontiers].
A notable nuance is that the same platform is already being discussed publicly beyond wound care. Tulane's July 2026 announcement tied LumaWave to a $1.5 million ARPA-H award focused on fetal monitoring during pregnancy and labor, suggesting the company is positioning photoacoustic oxygenation measurement as a broader sensing architecture rather than a single-use wound tool [Tulane Research, July 2026]. That said, the public evidence in this section supports device concept, modality, and intended use cases more clearly than it supports performance, regulatory status, or commercial readiness.
Partially corroborated -- Product modality and intended use are supported by Tulane Research and Biz New Orleans, while several benefit claims remain company-only.
Market Research
PUBLIC
The market matters because LumaWave is aiming at a clinical workflow where speed, portability, and oxygenation data can change treatment decisions, yet the available public record is still early enough that market sizing has to be handled through adjacent categories rather than company-specific forecasts [Biz New Orleans, November 2025] [Tulane Research, July 2026].
Public sources support the initial wedge more clearly than they support a formal TAM. LumaWave is positioning its handheld photoacoustic probe around chronic-wound care and point-of-care tissue oximetry, arguing that existing approaches such as transcutaneous oximetry are slower and less practical for high-volume settings [Biz New Orleans, November 2025] [LumaWave Inc.]. The same source set broadens the addressable clinical context to hospitals, community clinics, nursing homes, home-health agencies, and remote-care settings, which suggests a market that cuts across wound management, bedside diagnostics, and outpatient monitoring rather than a single reimbursement bucket [Biz New Orleans, November 2025] [F6S]. That is commercially relevant, but it also means investors should treat any market claim as a stack of adjacent budgets until there is evidence of a repeatable buying motion.
The demand signal in the public record is less about headline market size and more about unmet clinical need. Tulane's July 2026 disclosure describes the underlying system as a handheld photoacoustic imaging probe for real-time tissue oximetry that can identify low-oxygen areas by sending light into tissue and detecting resulting ultrasound signals [Tulane Research, July 2026]. A recent Frontiers review provides the broader technical backdrop, describing photoacoustic imaging as a modality that combines optical absorption with acoustic detection and has moved from preclinical work toward clinical applications, particularly when paired with ultrasound workflows [Frontiers]. That does not establish adoption on its own, but it does support the basic premise that clinicians are looking for functional tissue information that conventional structural imaging does not directly provide.
The adjacent-market story is one of optionality, though still mostly pre-commercial. Beyond chronic wounds, public sources point to fetal oxygenation during pregnancy and labor, peripheral artery disease, neonatal care, and veterinary surgery as potential application areas for photoacoustic imaging or for LumaWave's platform specifically [Tulane Research, July 2026] [Biz New Orleans, November 2025]. The July 2026 ARPA-H-backed fetal-monitoring project matters here because it indicates that the core technology may travel into obstetrics, a much larger and more regulated care pathway than wound assessment [Tulane Research, July 2026]. The caution is straightforward: adjacency expands theoretical market scope, but each indication likely requires its own evidence base, workflow integration, and regulatory path.
Regulatory and macro forces cut both ways. On the favorable side, point-of-care diagnostics continue to benefit from provider interest in lower-cost, decentralized tools that can be used outside tertiary centers, including in community and remote settings [news.tulane.edu, retrieved 2026] [Biz New Orleans, November 2025]. On the constraining side, this is still a medical-device commercialization path, which usually means longer validation cycles, dependence on clinical champions, and reimbursement or procurement friction before broad rollout. The public record also shows that current momentum has come from university support, pitch competitions, and an ARPA-H-linked research award rather than disclosed commercial deployments, so the market opportunity is plausible but not yet demand-proven [Tulane Research, July 2026] [Biz New Orleans, March 2026] [innovation.tulane.edu].
| Market lens | Public evidence | Implication for LumaWave |
|---|---|---|
| Chronic-wound assessment | Initial commercialization focus in chronic-wound care [Biz New Orleans, November 2025] | Most concrete near-term entry point in the public record |
| Point-of-care imaging | Portable, lower-cost imaging positioned for bedside or remote use [news.tulane.edu, retrieved 2026] [LumaWave Inc.] | Could expand beyond specialized hospital departments if workflow holds |
| Obstetric monitoring | ARPA-H-linked fetal monitoring effort announced with Tulane in July 2026 [Tulane Research, July 2026] | Indicates larger adjacent market, but likely with higher evidence and regulatory burden |
| Broader photoacoustic imaging | Clinical translation discussed in review literature [Frontiers] | Supports modality relevance, not company-specific adoption |
The public evidence points to a credible need state and several adjacent budgets, but not yet to a clean, externally sized market model. For now, the market case rests more on workflow pain and modality relevance than on verified commercial category data.
Partially corroborated -- Section relies on Tulane Research, Biz New Orleans, Frontiers, F6S, and company materials; the market framing is partly corroborated by independent sources, but no third-party TAM/SAM/SOM figures were identified.
Competition and Substitutes
MIXED LumaWave is not competing first against a clearly disclosed startup set, it is competing against existing wound-assessment workflows and established ultrasound purchasing habits while trying to introduce photoacoustic imaging as a practical point-of-care category [Biz New Orleans, November 2025] [Tulane Research, July 2026] [Frontiers].
The nearest competitive map, on public evidence, splits into three layers. Incumbents are the clinical methods LumaWave is explicitly arguing against in chronic-wound care, especially transcutaneous oximetry and conventional ultrasound-based workflows, which Biz New Orleans described as the backdrop for the company’s pitch that current options are slow, expensive, or limited in showing tissue oxygenation [Biz New Orleans, November 2025]. Adjacent substitutes include standard point-of-care ultrasound systems, because LumaWave’s own positioning leans on portability and lower-cost deployment relative to more cumbersome imaging setups rather than on a claim that providers are buying a wholly separate capital budget line from day one [LumaWave Inc.] [news.tulane.edu, retrieved 2026]. Challengers, in the narrower sense of named startups building directly comparable products, are not identified in the supplied source set, which itself says the available search did not surface verified national business-press coverage or a stable peer set for this company [Tulane Research, July 2026].
The company’s clearest edge today is scientific origin and domain fit, not distribution. The platform comes out of Tulane-linked research, and the founding pair combine commercialization energy from Vinoin Devpaul Vincely with Carolyn Bayer’s biomedical engineering background and research record in optical imaging and bioinstrumentation [Tulane Research, July 2026] [LumaWave Inc.] That matters in a modality such as photoacoustics, where the underlying method is technically differentiated from standard imaging because it combines optical absorption with acoustic detection [Frontiers]. Still, the durability of that edge is not yet obvious on public evidence. Academic provenance can help with credibility, grant capture, and early validation, but it is perishable if larger imaging companies or better-capitalized device startups move faster on regulatory execution, clinical evidence, and channel access.
The main exposure is commercial, not conceptual. LumaWave has a stated wedge in chronic-wound care and has described a Louisiana go-to-market strategy through clinical-trial-site conversions and key-opinion-leader relationships, but the public materials do not identify signed customers, paid deployments, or an owned sales channel [Biz New Orleans, November 2025]. That leaves the company vulnerable to incumbent purchasing behavior. A hospital or clinic that already buys point-of-care ultrasound from established vendors may accept the clinical need yet still prefer an integrated vendor relationship over a new specialist platform, especially if reimbursement, workflow integration, and clinical validation remain in progress. In that sense, conventional ultrasound vendors are the most concrete competitive force in view, even if none are named in the current record.
The most plausible 18-month scenario is that the category winner is whichever group first turns tissue-oxygenation imaging from a promising research modality into a repeatable clinical workflow. If LumaWave can convert Tulane-linked validation, the ARPA-H-backed fetal monitoring work, and its point-of-care form factor into publishable evidence and early site adoption, LumaWave is the winner if clinical proof arrives before larger vendors treat photoacoustic capability as an attachable feature set [Tulane Research, July 2026]. The loser if that does not happen is not necessarily photoacoustics as a field, but LumaWave’s first commercial wedge in wound care: in that case, incumbent ultrasound-centered workflows likely keep budget and clinician attention by default, while LumaWave remains a technically interesting platform without enough market pull to define the segment [Biz New Orleans, November 2025] [Frontiers].
Partially corroborated -- Section relies on Tulane Research, Biz New Orleans, Frontiers, and company materials; no named direct competitors were confirmed in the supplied public sources.
Opportunity
PUBLIC
The prize here is not a better wound-care gadget, but a portable imaging platform that could make tissue oxygenation visible at the bedside across multiple care settings if LumaWave can convert an academic modality into a practical clinical workflow [Tulane Research, July 2026] [Biz New Orleans, November 2025].
The headline opportunity is straightforward. If the company can show that a handheld photoacoustic probe reliably identifies low-oxygen tissue in real time, and can do so in a portable, lower-cost format than incumbent approaches used for oxygenation assessment, it has a path to becoming the operating layer for point-of-care tissue vitality assessment in wound care first and adjacent monitoring categories later [Tulane Research, July 2026] [Biz New Orleans, November 2025] [LumaWave Inc.]. That outcome is still early, but it is not purely aspirational on the evidence available: the core modality is grounded in an established imaging approach that combines optical absorption with acoustic detection [Frontiers], the company has a defined initial wedge in chronic-wound care [Biz New Orleans, November 2025], and the same platform is already being advanced into fetal monitoring through a disclosed $1.5 million ARPA-H Making Obstetrics Care Smart award involving Tulane and LumaWave [Tulane Research, July 2026].
The upside branches into a small number of scale paths rather than one binary product bet. The table below frames the public evidence for each.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Wound-care beachhead | LumaWave becomes a standard assessment tool in high-volume wound clinics and hospital wound programs, replacing slower oxygenation workflows with bedside imaging | Early clinical adoption in chronic-wound assessment and workflow fit in settings that already use point-of-care imaging tools [Biz New Orleans, November 2025] | The company is explicitly positioning around chronic-wound care, and public reporting describes current methods as slow, expensive, and impractical for high-volume clinics, which creates a workflow-driven entry point if performance holds [Biz New Orleans, November 2025] |
| Obstetrics expansion | The probe platform extends into fetal monitoring, giving LumaWave a second, much larger clinical budget line beyond wound care | Technical and clinical progress under the ARPA-H MOCS-backed fetal monitoring effort with Tulane [Tulane Research, July 2026] | The July 2026 Tulane disclosure ties LumaWave directly to a funded effort aimed at measuring fetal-tissue oxygen levels during pregnancy and labor, which suggests the platform may generalize beyond its initial wedge [Tulane Research, July 2026] |
| Portable oxygenation platform | LumaWave becomes a multi-indication photoacoustic diagnostics company spanning peripheral artery disease, neonatal care, remote care, and other tissue-oxygenation use cases | A single validated hardware and software stack proves usable across several point-of-care settings [Biz New Orleans, November 2025] [LumaWave Inc.] | Public materials already describe adjacent applications including peripheral artery disease and remote settings, and the underlying technical claim is modality-based rather than tied to one disease alone [Biz New Orleans, November 2025] [LumaWave Inc.] |
What compounding looks like here is less a classic network effect than a modality-and-workflow flywheel. A first successful use case in wound care would give the company validation data, clinician champions, and a reason for providers to trial the same hardware architecture in adjacent settings; if that then expands into obstetrics or vascular use cases, each added indication can make the installed base more valuable and improve the economics of manufacturing, software refinement, and training [Biz New Orleans, November 2025] [Tulane Research, July 2026]. The earliest signs of that flywheel are visible, though still limited: LumaWave has moved from pitch-stage visibility in Louisiana startup forums to a disclosed federal-backed research program with Tulane, and its public materials present the platform as portable point-of-care imaging rather than a single-purpose sensor [Biz New Orleans, November 2025] [Tulane Research, July 2026] [LumaWave Inc.].
The size of the win is hard to anchor precisely because no credible public market-sizing figure or direct public comparable appears in the source set. Even so, the relevant economic frame is clear enough: if LumaWave were to become an accepted point-of-care platform for oxygenation assessment across wound care and at least one adjacent category such as fetal monitoring, the outcome could resemble a strategic medical-device acquisition for differentiated imaging infrastructure rather than a narrow software tool (scenario, not a forecast) [Tulane Research, July 2026] [Frontiers]. Public evidence is not yet strong enough to support a disciplined valuation range, but the combination of a clinically meaningful signal, portable hardware, and multiple indicated use cases is the part that makes the upside investable to study further rather than easy to dismiss [Biz New Orleans, November 2025] [Tulane Research, July 2026].
Partially corroborated -- Section relies on one independent local-business report, one Tulane institutional report, one review article for modality context, and company materials for some indication breadth.
Sources
Open sources
[Tulane Research, July 2026] Tulane and LumaWave awarded $1.5 million to improve fetal monitoring during labor | https://research.tulane.edu/news/1653969/Tulane%20and%20LumaWave%20awarded%20$1.5%20million%20to%20improve%20fetal%20monitoring%20during%20labor
[Biz New Orleans, March 2026] Thrivvy Leads Winners at Tulane $50K Demo Day | https://bizneworleans.com/thrivvy-leads-winners-at-tulane-50k-demo-day/
[F6S] LumaWave | https://www.f6s.com/company/lumawave
[Biz New Orleans, November 2025] Idea Village Spotlights Fall 2025 Pitch Night Startups | https://bizneworleans.com/idea-village-spotlights-fall-2025-pitch-night-startups/
[LumaWave Inc.] LumaWave Inc. - Point-of-Care Tissue Vitality Assessment | https://www.lumawaveimaging.com/
[Frontiers] Dual-modal photoacoustic and ultrasound imaging: from preclinical to clinical applications | https://www.frontiersin.org/journals/photonics/articles/10.3389/fphot.2024.1359784/full
[innovation.tulane.edu] Open Season Pitch Competition | https://innovation.tulane.edu/tulane-students-and-faculty-compete-open-season-pitch-competition
Articles about LumaWave
- LumaWave's Handheld Probe Is Chasing Tissue Oxygen at the Point of Care — The Tulane spinout, backed by non-dilutive grants, aims to turn a lab technique into a tool for wound care and fetal monitoring.